ClinicalTrials.gg
Active, not recruitingNCT05759520Updated Oct 1, 2024

Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants

A Phase 3 interventional study of 13-valent pneumococcal conjugate vaccine (multivalent conjugate) and Prevenar 13 in Streptococcus Pneumoniae Infection, sponsored by Fosun Adgenvax Biopharmaceutical Co.,Ltd.. Active, not recruiting at 5 sites in China. Open to participants aged 6 Weeks to 3 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Fosun Adgenvax Biopharmaceutical Co.,Ltd. (part of Fosun Pharma) · Phase 3, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as active, not recruiting.
  • Registered 3 months after the study started (first participant enrolled Nov 2022, registered Feb 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,800
Allocation
Randomized
Ages
6 Weeks to 3 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Pneumococcal Infections with a site in China — 6 open to participants now, 9 under way, 4 of them phase 3. Pneumococcal Infections · China.

Planned enrollment
5th of 33
1,800 · median 480
Started
2022
with 3 others
Phase 3
9 of 36
3 open now
Registered
17th of 36
by date
Lead sponsor
1 of 36
Fosun Adgenvax Biopharmaceutical Co.,Ltd.

Among the 36 studies in Pneumococcal Infections with a site in China, this one is the 5th largest by planned enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2022, is one of 9 in phase 3, and was the 17th registered.

Pneumococcal Infections

298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

6 of the 36 studies in Pneumococcal Infections with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 6 Weeks to 3 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Pneumococcal Infections with a site in China, or all of them as a file.
02

Study summary

This study is a phase III clinical trial to evaluate the immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine (multivalent conjugate) in infants aged 2 months (at least 6 weeks) and 3 months. The main objectives of the study include: 1. To evaluate the immunogenicity of the trial vaccine in infants aged 2 months (at least 6 weeks) following the corresponding immunization schedule compared to the control vaccine; 2. To evaluate the immunogenicity of the trial vaccine in infants aged 3 months following the corresponding immunization schedule compared to the 2-month group; 3. To evaluate the safety of the trial vaccine in infants aged 2 months (at least 6 weeks) and 3 months following the corresponding immunization schedule.

03

Conditions studied

  • Streptococcus Pneumoniae Infection
04

Who can participate

Ages eligible
6 Weeks to 3 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Primary immunization phase:

  1. The subject's legal guardian voluntarily agreed to allow his child to participate in the study and signed an form.
  2. The subject's legal guardian has the ability to understand the study procedures and to participate in all planned follow-up visits.
  3. Full-term pregnancy (37 weeks to 42 weeks gestation) and the birth weight was 2500g\~4000g.
  4. On the day of the first dose of vaccination, it meets the observation age of this clinical trial (2\~3 months of age, with a minimum of 6 weeks) and be able to provide legal identification;
  5. Not having received a non- within 7 days prior to enrollment and not having received a live vaccine within 14 days;
  6. The body temperature \<37.5°C (axillary body temperature) on the day of enrollment.

Booster immunization phase:

  1. Infants and children who have completed the full process of basic immunization in this clinical trial and are 12 to 15 months of age;
  2. According to the opinion of the investigator, the subject's legal guardians and their families can comply with the requirements of the clinical trial protocol.

Exclusion criteria

Exclusion Criteria:

Primary immunization phase:

  1. The baby is born in abnormal labor (dystocia, instrumental delivery) or has a history of asphyxia and nervous system damage, and is now suffering from pathologic jaundice, perianal abscess and severe eczema;
  2. Have been vaccinated against pneumococcus in the past or have a history of invasive diseases caused by pneumococcus in the past (confirmed by either clinical, serological or microbiological methods);
  3. Previous history of severe allergy to any vaccine or drug, such as anaphylactic shock, allergic laryngeal edema, allergic purpura and local allergic necrosis reaction (Arthus reaction);
  4. Suffering from congenital or acquired immunodeficiency, or receiving treatment, such as systemic treatment for more than 2 weeks one month before vaccination, such as prednisone or similar drugs > 5mg/day (use of local and inhaled/atomized steroids is eligible for enrollment);
  5. Have received blood or blood-related products or immunoglobulin treatment before joining the group ( immunoglobulin is acceptable);
  6. Suffering from severe congenital malformation, severe developmental disorders, serious genetic diseases (such as severe thalassemia), severe malnutrition, etc.;
  7. Suffering from infectious diseases such as tuberculosis and viral hepatitis, or parents infected with ;
  8. Having to intramuscular injections such as thrombocytopenia, any coagulation disorder or receiving anticoagulant therapy;
  9. Those with a history or family history of convulsions, epilepsy, encephalopathy and psychosis;
  10. Asplenia, functional asplenia, and asplenia or splenectomy for any reason;
  11. Subjects with other safety risks or conditions that, in the opinion of the investigator, may interfere with the assessment of the purpose of the study.

Booster immunization phase:

  1. Subject received any other pneumonia vaccine after primary immunization and before booster immunization;
  2. Subject has received blood or blood-related products or immunoglobulin treatment within 3 months before booster immunization;
  3. The subjects have known or suspected immunological functional defects since they participated in this clinical trial, including receiving immunosuppressant treatment (such as systemic glucocorticoid treatment for more than 2 weeks in one month before vaccination, such as prednisone or similar drugs > 5mg/day) and their parents are HIV-infected;
  4. According to the researcher's judgment, the subjects have any other factors that are not suitable for clinical trials.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,800 participants (estimated)

Study arms

  • Experimental
    2-month-old experimental group

    Vaccination of 4 doses of experimental vaccine(0,2,4,1 booster dose)

    Biological: 13-valent pneumococcal conjugate vaccine (multivalent conjugate)

  • Active comparator
    2-month-old control group

    Vaccination of 4 doses of control vaccine(0,2,4,1 booster dose)

    Biological: Prevenar 13

  • Experimental
    3-month-old group

    Vaccination of 4 doses of experimental vaccine(0,1,2,1 booster dose)

    Biological: 13-valent pneumococcal conjugate vaccine (multivalent conjugate)

Interventions

  • Biological13-valent pneumococcal conjugate vaccine (multivalent conjugate)

    the 2-month-old experimental group and the 3-month-old group received the experimental vaccine

  • BiologicalPrevenar 13

    the 2-month-old control group received the active control vaccine

06

What researchers measure

Primary outcomes

  1. seroprotection rate of 13 vaccine serotype-specific pneumococcal IgG antibodies

    Immunogenicity

    Time frame: 30 days after primary immunization

  2. 13 vaccine serotype-specific pneumococcal IgG antibodies GMC

    Immunogenicity

    Time frame: 30 days after primary immunization

  3. incidence of adverse events (AE)

    Safety

    Time frame: 30 minutes/0~7 days/0~30 days after each dose of vaccination

  4. incidence of all serious adverse events (SAEs)

    Safety

    Time frame: from the first dose to 6 months after primary immunization

  5. incidence of all serious adverse events (SAEs)

    Safety

    Time frame: from the first dose of vaccination to 12 months after the booster immunization

Secondary outcomes

  1. percentage of subjects with 13 vaccine serotype-specific pneumococcal IgG antibody concentrations ≥1.0 μg/ml

    Primary stage

    Time frame: 30 days after primary immunization

  2. the positivity rate of pneumococcal OPA antibodies for 13 vaccine serotypes

    Primary stage

    Time frame: 30 days after primary immunization

  3. the GMT of pneumococcal OPA antibodies for 13 vaccine serotypes

    Primary stage

    Time frame: 30 days after primary immunization

  4. the seroconversion rate of pneumococcal OPA antibodies for 13 vaccine serotypes

    Primary stage

    Time frame: 30 days after primary immunization

  5. seroprotection rate of 13 vaccine serotype-specific pneumococcal IgG antibodies

    Booster stage

    Time frame: 30 days after booster immunization

  6. percentage of subjects with 13 vaccine serotype-specific pneumococcal IgG antibody concentrations ≥ 1.0 μg/mL

    Booster stage

    Time frame: 30 days after booster immunization

  7. GMC of 13 vaccine serotype-specific pneumococcal IgG antibodies

    Booster stage

    Time frame: 30 days after booster immunization

  8. the positivity rate of pneumococcal OPA antibodies for 13 vaccine serotypes

    Booster stage

    Time frame: 30 days after booster immunization

  9. the GMT of pneumococcal OPA antibodies for 13 vaccine serotypes

    Booster stage

    Time frame: 30 days after booster immunization

07

Study locations

5 sites
  • Yizhou District Disease Prevention Control Center
    Hechi City, Guangxi Zhuang Autonomous Region 547000, China
  • Zhongshan County Center for Disease Control and Prevention
    Hezhou City, Guangxi Zhuang Autonomous Region 542800, China
  • Luzhai County Disease Prevention Control Center
    Liuzhou City, Guangxi Zhuang Autonomous Region 545000, China
  • Binyang County Center for Disease Control and Prevention
    Nanning City, Guangxi Zhuang Autonomous Region 530000, China
  • Wuming District Center for Disease Control and Prevention
    Nanning City, Guangxi Zhuang Autonomous Region 530000, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Jun 2025, 31 months after the start.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's planned 31 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2023
First posted
Mar 8, 2023
StartActual
Nov 4, 2022
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05759520
Responsible party
Sponsor
First posted
Mar 8, 2023
Start date
Nov 4, 2022
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Oct 1, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion